NASDAQ:BLTE

Belite Bio (BLTE) Stock Forecast, Price & News

$31.50

+2.30 (+7.88%)

(As of 09/22/2023 ET)

Compare

Today's Range: $29.37
▼
$31.69
50-Day Range: $14.40
▼
$36.64
52-Week Range: $11.00
▼
$38.63

Volume: 42,944 shs
Average Volume: 91,168 shs
Market Capitalization: $857.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $41.00

Belite Bio MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 30.2% Upside
$41.00 Price Target
Short Interest: Healthy
0.14% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.01
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.27) to ($0.50) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

208th out of 965 stocks

Biotechnology Industry

2nd out of 15 stocks

4.5

Analyst's Opinion

Consensus Rating
Belite Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $41.00, Belite Bio has a forecasted upside of 30.2% from its current price of $31.50.
Amount of Analyst Coverage
Belite Bio has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
0.14% of the outstanding shares of Belite Bio have been sold short.
Short Interest Ratio / Days to Cover
Belite Bio has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Belite Bio has recently increased by 7.14%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Belite Bio does not currently pay a dividend.
Dividend Growth
Belite Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BLTE.

2.2

News and Social Media Coverage

News Sentiment
Belite Bio has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Belite Bio this week, compared to 0 articles on an average week.
Search Interest
5 people have searched for BLTE on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Belite Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -82% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Belite Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
13.29% of the stock of Belite Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 3.82% of the stock of Belite Bio is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Belite Bio are expected to grow in the coming year, from ($1.27) to ($0.50) per share.
Price to Book Value per Share Ratio
Belite Bio has a P/B Ratio of 18.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Belite Bio (NASDAQ:BLTE) Stock

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

BLTE Price History

30 days | 90 days | 365 days | Advanced Chart

BLTE Stock News Headlines

September 20, 2023 | americanbankingnews.com

Belite Bio, Inc (NASDAQ:BLTE) Receives Consensus Recommendation of "Buy" from Brokerages

August 22, 2023 | seekingalpha.com

Belite Bio: The Pick Of The Post-IPO Biotechs - Is There Further Upside Ahead?

September 23, 2023 | Altimetry (Ad)

Seven millionaires secretly enable market shock?

A fraud expert to the FBI just shared a surprising new prediction. Own stocks? Watch it now.

August 13, 2023 | seekingalpha.com

Belite Bio, Inc 2023 Q2 - Results - Earnings Call Presentation

August 12, 2023 | fool.com

Belite Bio (NASDAQ: BLTE)

August 11, 2023 | markets.businessinsider.com

Expert Ratings for Belite Bio

August 8, 2023 | finance.yahoo.com

Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results

August 4, 2023 | finance.yahoo.com

Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results

September 23, 2023 | Chaikin Analytics (Ad)

This is the #1 Stock to Buy for the AI Tidal Wave

Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.

July 31, 2023 | finance.yahoo.com

Is Belite Bio, Inc (NASDAQ:BLTE) Worth US$24.1 Based On Its Intrinsic Value?

July 29, 2023 | markets.businessinsider.com

Belite Bio Incorporation American Depository Receipt Repr 1 Sh

July 28, 2023 | finance.yahoo.com

Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA

July 27, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Belite Bio

July 24, 2023 | finance.yahoo.com

Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease

June 30, 2023 | finance.yahoo.com

Why Shares of Belite Bio Soared This Week

June 20, 2023 | markets.businessinsider.com

Analyst Expectations for Belite Bio's Future

June 15, 2023 | seekingalpha.com

Belite Bio: Undercovered Eye Disease Company With Early Data

May 31, 2023 | finance.yahoo.com

Why Shares of Belite Bio Are Slumping Wednesday

May 31, 2023 | msn.com

Belite Bio down 38%, prices $30M offering

May 31, 2023 | marketwatch.com

Belite Bio ADSs Plunge Premarket After Public Offering Priced >BLTE

May 31, 2023 | finance.yahoo.com

Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants

May 30, 2023 | msn.com

Belite Bio commences public offering of American Depositary Shares

May 30, 2023 | finance.yahoo.com

Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants

May 14, 2023 | seekingalpha.com

Belite Bio, Inc 2023 Q1 - Results - Earnings Call Presentation

May 11, 2023 | finance.yahoo.com

Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results

May 10, 2023 | finance.yahoo.com

Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results

May 4, 2023 | finance.yahoo.com

Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data

See More Headlines

Receive BLTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter.

BLTE Company Calendar

Last Earnings: 8/08/2023
Today: 9/23/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:BLTE
CUSIP: N/A
CIK: 1889109
Web: belitebio.com
Phone: 858-246-6240
Fax: N/A
Employees: 5
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $41.00
High Stock Price Forecast: $57.00
Low Stock Price Forecast: $25.00
Forecasted Upside/Downside: +30.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 20.35
Quick Ratio: 20.35

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.67 per share
Price / Book: 18.86

Miscellaneous

Outstanding Shares: 27,230,000
Free Float: 23,610,000
Market Cap: $857.75 million
Optionable: Not Optionable
Beta: -2.10

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Dr. Yu-Hsin Lin M.B.A. (Age 44)
Ph.D., Chairman of Directors & CEO

Mr. Hao-Yuan Chuang C.F.A. (Age 39)
F.R.M., M.B.A., CFO & Director

Dr. Nathan L. Mata Ph.D. (Age 57)
Chief Scientific Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

BLTE Stock - Frequently Asked Questions

Should I buy or sell Belite Bio stock right now?: 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Belite Bio in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLTE shares.
View BLTE analyst ratings or view top-rated stocks.
What is Belite Bio's stock price forecast for 2023?: 6 Wall Street research analysts have issued 1 year price targets for Belite Bio's stock. Their BLTE share price forecasts range from $25.00 to $57.00. On average, they anticipate the company's share price to reach $41.00 in the next year. This suggests a possible upside of 30.2% from the stock's current price.
View analysts price targets for BLTE or view top-rated stocks among Wall Street analysts.
How have BLTE shares performed in 2023?: Belite Bio's stock was trading at $30.1450 at the beginning of the year. Since then, BLTE shares have increased by 4.5% and is now trading at $31.50.
View the best growth stocks for 2023 here.
Are investors shorting Belite Bio?: Belite Bio saw a increase in short interest in August. As of August 31st, there was short interest totaling 37,500 shares, an increase of 7.1% from the August 15th total of 35,000 shares. Based on an average daily volume of 81,900 shares, the days-to-cover ratio is currently 0.5 days.
View Belite Bio's Short Interest.
When is Belite Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our BLTE earnings forecast.
How were Belite Bio's earnings last quarter?: Belite Bio, Inc (NASDAQ:BLTE) issued its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.03.

When did Belite Bio IPO?: (BLTE) raised $36 million in an initial public offering on Friday, April 29th 2022. The company issued 6,000,000 shares at $5.50-$6.50 per share.
What is Belite Bio's stock symbol?: Belite Bio trades on the NASDAQ under the ticker symbol "BLTE."
Who are Belite Bio's major shareholders?: Belite Bio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Atria Wealth Solutions Inc. (3.27%) and State Street Corp (0.05%).
How do I buy shares of Belite Bio?: Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Belite Bio's stock price today?: One share of BLTE stock can currently be purchased for approximately $31.50.
How much money does Belite Bio make?: Belite Bio (NASDAQ:BLTE) has a market capitalization of $857.75 million.
How can I contact Belite Bio?: The official website for the company is belitebio.com. The company can be reached via phone at 858-246-6240 or via email at ir@belitebio.com.

This page (NASDAQ:BLTE) was last updated on 9/23/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial